Novo Nordisk has been in the spotlight for its obesity treatments, yet the share price slide over the past few years raises a basic question for holders and would‑be buyers: Is the current valuation still supported by what the business is earning today?
- The stock has fallen 57.4% over the past 3 years, which puts the focus squarely on whether that drop has brought the price closer to what the earnings can justify.
- Fresh data on the CagriSema obesity drug, showing 25% average weight loss in women over 68 weeks, can influence how investors think about the company’s future profit potential and how much they are willing to pay for each dollar of earnings.
- The analysts covering Novo Nordisk have run their own numbers. See what analysts think Novo Nordisk's shares could be worth.
The issue now is whether Novo Nordisk’s recent share price, after these moves and developments, lines up with what its earnings suggest is a reasonable level.
If you are weighing Novo Nordisk against other obesity and GLP-1 related opportunities, it can help to compare how the market prices similar stories using 34 healthcare AI stocks.
Does Novo Nordisk Look Undervalued on Earnings?
The P/E ratio is a useful yardstick for Novo Nordisk because investors are focused on how much they are paying for each dollar of current earnings. On this measure, Novo Nordisk trades on about 9.9x earnings, which is well below the wider pharmaceuticals industry average of roughly 15.5x and also far under the peer group near 50.8x. Because the CagriSema data has sharpened interest in Novo Nordisk’s obesity portfolio, that gap shows the market is still pricing the stock at a lower earnings multiple than many comparable healthcare plays.
The Fair Ratio, which reflects what a tailored P/E might look like once margins, scale, growth profile and sector risk are all taken into account, points to Novo Nordisk changing hands at a level below that customised benchmark. Because the recent CagriSema results have lifted expectations around the obesity franchise while the P/E remains beneath this modelled range, the shares currently screen as undervalued on this metric. Explore the numbers behind Novo Nordisk's P/E valuation.
The Novo Nordisk Narrative: What Would Justify Today's Price?
Novo Nordisk’s valuation puzzle sets up the role of Simply Wall St Narratives. These short stories spell out which future paths for growth, margins and earnings would need to play out for Novo Nordisk to be worth meaningfully more or less than today’s price. Each one treats fair value as a thesis about the business that you can watch over time, rather than a single frozen number on a chart. Narratives sit on Simply Wall St’s Community page, ready for you to explore when you want to stress test your own view.
One of the top community narratives on Novo Nordisk: 59% undervalued
"Current sentiment has swung deeply negative, but expectations are now low, and the embedded upside is material..."
Discover why this Narrative puts Novo Nordisk at 59% undervalued.
Novo Nordisk’s valuation still leaves one crucial issue unresolved
Price tags and earnings multiples tell only part of the story for Novo Nordisk, because recent research has also highlighted specific business concerns that investors may want to review before leaning on the valuation alone. Take a closer look at 2 warning signs (1 major) before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com